| Ytd | 8.39% | |
| 1y | 18.56% |
| Open | 118.19 | Prev Close | 117.60 | Low | 114.00 | High | 119.75 | Mkt Cap | 7.96B |
| Vol | 751.99K | Avg Vol | 782.13K | EPS | -3.11 | P/E | -37.31 | Forward P/E | -189.75 |
| Beta | 1.97 | Short Ratio | 14.32 | Inst. Own | 115.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 103.45 | 200-d Avg | 99.12 | 1yr Est | 141.53 |
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported second-quarter 2026 global net product sales of $71.3
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 m
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zac
Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body we
-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong wi
-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likel
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Tr
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sus
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company report
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for it
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss a
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings a
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
On Friday morning, 155 companies achieved new lows for the year.
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Wednesday
60 Biggest Movers From Yesterday